DOCSLIB.ORG

Delayed Puberty

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Delayed Puberty TERO VARIMO UNIVERSITY OF HELSINKI DELAYED PUBERTY PUBERTY DELAYED GROWTH WITH INTERACTIONS AND OUTCOME ETIOLOGY, DELAYED PUBERTY ETIOLOGY, OUTCOME AND INTERACTIONS WITH GROWTH TERO VARIMO ISBN 978-951-51-2838-6 (paperback) ISBN 978-951-51-2839-3 (PDF) http://ethesis.helsinki.fi Painosalama Oy Helsinki 2016 HELSINKI 2016 2016 Pediatric Graduate School Doctoral Programme in Clinical Research Children’s Hospital Helsinki University Hospital and University of Helsinki Helsinki, Finland DELAYED PUBERTY ETIOLOGY, OUTCOME AND INTERACTIONS WITH GROWTH Tero Varimo ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Medicine of the University of Helsinki, for public examination at the Niilo Hallman Auditorium, Children’s Hospital, on January 20th 2017, at 12 noon. Helsinki 2016 Supervised by Professor Taneli Raivio MD, PhD Matti Hero Children’s Hospital Children’s Hospital Helsinki University Hospital Helsinki University Hospital and Department of Physiology Helsinki, Finland Faculty of Medicine University of Helsinki Helsinki, Finland Reviewed by Professor Juha Tapanainen Docent Marja Ojaniemi Department of Obstetrics and Oulu University Hospital Gynecology and PEDEGO Research Unit, Medical Helsinki University Hospital Research Center Oulu, University of Helsinki University of Oulu Helsinki, Finland Oulu, Finland Official opponent Docent Antti Perheentupa Department of Obstetrics and Gynecology Turku University Hospital University of Turku Turku, Finland ISBN 978-951-51-2838-6 (Paperback) ISBN 978-951-51-2839-3 (PDF) Painosalama Oy Helsinki 2016 To Eveliina and Joonatan TABLE OF CONTENTS ABBREVIATIONS ................................................................................................ 7 ABSTRACT .......................................................................................................... 9 FINNISH SUMMARY (TIIVISTELMÄ) ................................................................ 11 INTRODUCTION ................................................................................................ 13 REVIEW OF THE LITERATURE ....................................................................... 15 1. HYPOTHALAMIC-PITUITARY-GONADAL (HPG) AXIS AND PUBERTY 15 1.1. Current concepts on the development and function of GnRH neurons .............................................................................................. 15 1.1.1. The ontogeny and migration of GnRH neurons ...................... 15 1.1.2. The composition and function of the GnRH pulse generator .. 16 1.1.3. The activation phases of the HPG axis ................................... 18 1.1.4. The regulation of the HPG axis ............................................... 19 1.2. Normal puberty .................................................................................. 19 1.2.1. General concepts .................................................................... 19 1.2.2. Normal variation in the timing of puberty and secular trends . 19 1.2.3. Clinical and biochemical markers of puberty .......................... 20 1.2.4. Molecular genetic basis of puberty ......................................... 21 1.3. Delayed puberty (DP) ........................................................................ 24 1.3.1. Diagnostic criteria in Finland ................................................... 24 1.3.2. Underlying causes .................................................................. 24 1.3.3. Evaluation of patient with DP .................................................. 25 1.3.4. Treatment ................................................................................ 27 1.4. Congenital hypogonadotropic hypogonadism (CHH) ........................ 27 1.4.1. Diagnostic criteria ................................................................... 28 1.4.2. Clinical and biochemical evaluation ........................................ 28 1.4.3. Clinical features ...................................................................... 29 1.4.4. The differential diagnosis between CHH and constitutional delay of growth and puberty ................................................... 29 1.4.5. Treatment ................................................................................ 30 1.4.6. Long-term impact of sex steroid deficiency on bone-health and health-related quality of life .............................................. 31 2. THE HORMONAL REGULATION OF GROWTH ...................................... 31 2.1. Fetal life and infancy .......................................................................... 31 2.2. Childhood ........................................................................................... 32 2.3. Puberty .............................................................................................. 33 2.4. Adult height ........................................................................................ 34 2.5. Evaluation of growth .......................................................................... 34 AIMS OF THE STUDY ....................................................................................... 36 PATIENTS AND METHODS .............................................................................. 37 3. STUDY SUBJECTS ................................................................................... 37 3.1. Boys with idiopathic short stature (ISS) (I) ........................................ 37 3.1.1. Collection and analyses of the serum samples ...................... 37 3.2. Patients with DP (II) ........................................................................... 37 TABLE OF CONTENTS 3.2.1. Classification of different DP types .......................................... 39 3.3. Patients with CHH (III-V) .................................................................... 40 3.3.1. Acquisition of growth data ....................................................... 40 3.3.2. Health-related quality of life ..................................................... 41 4. STATISTICS .............................................................................................. 41 5. ETHICS ...................................................................................................... 42 RESULTS ........................................................................................................... 43 1. Serum MKRN3 levels in boys before the clinical onset of puberty ............ 43 2. The underlying causes of DP ..................................................................... 45 3. The differential diagnosis of DP ................................................................. 46 4. The growth of patients with CHH from birth to adult height ....................... 48 5. Health-related quality of life in males with CHH ......................................... 50 DISCUSSION ...................................................................................................... 53 1. Circulating MKRN3 levels in boys before the clinical onset puberty .......... 53 2. The diagnoses and predictors of DP .......................................................... 55 3. The influence of sex steroid deficiency on growth during minipuberty, childhood and adolescence ........................................................................ 57 4. Health-related quality of life in males with CHH ......................................... 58 5. Future perspectives .................................................................................... 59 ACKNOWLEDGEMENTS................................................................................... 60 REFERENCES .................................................................................................... 62 ORIGINAL PUBLICATIONS............................................................................... 79 LIST OF ORIGINAL PUBLICATIONS This thesis is based on the following articles which are referred to in the text by Roman numerals I-V: I. Varimo T, Dunkel L, Vaaralahti K, Miettinen PJ, Hero M, Raivio T. Circulating makorin ring finger protein 3 (MKRN3) levels decline in boys before the clinical onset of puberty. Eur J Endocrinol. 2016;174:785-90. II. Varimo T, Miettinen PJ, Känsäkoski J, Raivio T, Hero M. Congenital hypogonadotropic hypogonadism, functional hypogonadotropism, or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center. Hum Reprod. In press. III. Varimo T, Hero M, Laitinen EM, Miettinen PJ, Tommiska J, Känsäkoski J, Juul A, Raivio T. Childhood growth in boys with congenital hypogonadotropic hypogonadism. Pediatr Res. 2016;79:705-9. IV. Hero M, Laitinen EM, Varimo T, Vaaralahti K, Tommiska J, Raivio T. Childhood growth of females with Kallmann syndrome and FGFR1 mutations. Clin Endocrinol (Oxf). 2015;82:122-6. V. Varimo T, Hero M, Laitinen EM, Sintonen H, Raivio T. Health-related quality of life in male patients with congenital hypogonadotropic hypogonadism. Clin Endocrinol (Oxf). 2015;83:141-3. 6 ABBREVIATIONS AI aromatase inhibitor AMH anti-müllerian hormone ANOS1 anosmin 1 ARC arcuate nucleus BDI beck’s depression index BMD bone mineral density BMI body mass index CAH congenital adrenal hyperplasia CDGP constitutional delay of growth and puberty CHD7 chromodomain helicase DNA-binding protein 7 CHH congenital hypogonadotropic hypogonadism CI confidence interval CNS central nervous system CPP central precocious puberty DP delayed puberty DYN dynorphin ELISA enzyme-linked immunosorbent assay FGFR1 fibroblast growth factor receptor 1 FHH functional
Load more

Recommended publications
  • Blueprint Genetics ANOS1 Single Gene Test
    ANOS1 single gene test Test code: S00125 Phenotype information Kallmann syndrome Alternative gene names KALIG-1, WFDC19 Some regions of the gene are duplicated in the genome leading to limited sensitivity within the regions. Thus, low-quality variants are filtered out from the duplicated regions and only high-quality variants confirmed by other methods are reported out. Read more. Panels that include the ANOS1 gene Kallmann Syndrome Panel Abnormal Genitalia/ Disorders of Sex Development Panel Test Strengths The strengths of this test include: CAP accredited laboratory CLIA-certified personnel performing clinical testing in a CLIA-certified laboratory Powerful sequencing technologies, advanced target enrichment methods and precision bioinformatics pipelines ensure superior analytical performance Careful construction of clinically effective and scientifically justified gene panels Our Nucleus online portal providing transparent and easy access to quality and performance data at the patient level Our publicly available analytic validation demonstrating complete details of test performance ~2,000 non-coding disease causing variants in our clinical grade NGS assay for panels (please see ‘Non-coding disease causing variants covered by this test’) Our rigorous variant classification scheme Our systematic clinical interpretation workflow using proprietary software enabling accurate and traceable processing of NGS data Our comprehensive clinical statements Test Limitations This test does not detect the following: Complex inversions Gene conversions
    [Show full text]
  • MR Imaging of Kallmann Syndrome, a Genetic Disorder of Neuronal Migration Affecting the Olfactory and Genital Systems
    MR Imaging of Kallmann Syndrome, a Genetic Disorder of Neuronal Migration Affecting the Olfactory and Genital Systems 1 2 2 3 4 Charles L. Truwit, ' A. James Barkovich, Melvin M. Grumbach, and John J. Martini PURPOSE: We report the MR findings in nine patients with clinical and laboratory evidence of Kallmann syndrome (KS), a genetic disorder of olfactory and gonadal development. In patients with KS, cells that normally express luteinizing hormone-releasing hormone fail to migrate from the medial olfactory placode along the terminalis nerves into the forebrain. In addition, failed neuronal migration from the lateral olfactory placode along the olfactory fila to the forebrain results in aplasia or hypoplasia of the olfactory bulbs and tracts. Patients with KS, therefore, suffer both reproductive and olfactory dysfunction. METHODS: Nine patients with KS underwent direct coronal MR of their olfactory regions in order to assess the olfactory sulci, bulbs, and tracts. A lOth patient had MR findings of KS, although the diagnosis is not yet confirmed by laboratory tests. RESULTS: Abnormalities of the olfactory system were identified in all patients. In particular, the anterior portions of the olfactory sulci were uniformly hypoplastic. The olfactory bulbs and tracts appeared hypoplastic or aplastic in all patients in whom the bulb/ tract region was satisfactorily imaged. In two (possibly three) patients, prominent soft tissue in the region of the bulbs suggests radiographic evidence of neurons that have been arrested before migration. CONCLUSIONS: Previous investigators of patients with KS used axial MR images to demonstrate hypoplasia of the olfactory sulci but offered no assessment of the olfactory bulbs.
    [Show full text]
  • Novel Mutations in ANOS1 and FGFR1 Genes Agnieszka Gach1* , Iwona Pinkier1, Maria Szarras-Czapnik2, Agata Sakowicz3 and Lucjusz Jakubowski1
    Gach et al. Reproductive Biology and Endocrinology (2020) 18:8 https://doi.org/10.1186/s12958-020-0568-6 RESEARCH Open Access Expanding the mutational spectrum of monogenic hypogonadotropic hypogonadism: novel mutations in ANOS1 and FGFR1 genes Agnieszka Gach1* , Iwona Pinkier1, Maria Szarras-Czapnik2, Agata Sakowicz3 and Lucjusz Jakubowski1 Abstract Background: Congenital hypogonadotropic hypogonadism (CHH) is a rare disease, triggered by defective GnRH secretion, that is usually diagnosed in late adolescence or early adulthood due to the lack of spontaneous pubertal development. To date more than 30 genes have been associated with CHH pathogenesis with X-linked recessive, autosomal dominant, autosomal recessive and oligogenic modes of inheritance. Defective sense of smell is present in about 50–60% of CHH patients and called Kallmann syndrome (KS), in contrast to patients with normal sense of smell referred to as normosmic CHH. ANOS1 and FGFR1 genes are all well established in the pathogenesis of CHH and have been extensively studied in many reported cohorts. Due to rarity and heterogenicity of the condition the mutational spectrum, even in classical CHH genes, have yet to be fully characterized. Methods: To address this issue we screened for ANOS1 and FGFR1 variants in a cohort of 47 unrelated CHH subjects using targeted panel sequencing. All potentially pathogenic variants have been validated with Sanger sequencing. Results: Sequencing revealed two ANOS1 and four FGFR1 mutations in six subjects, of which five are novel and one had been previously reported in CHH. Novel variants include a single base pair deletion c.313delT in exon 3 of ANOS1, three missense variants of FGFR1 predicted to result in the single amino acid substitutions c.331C > T (p.R111C), c.1964 T > C (p.L655P) and c.2167G > A (p.E723K) and a 15 bp deletion c.374_388delTGCCCGCAGACTCCG in exon 4 of FGFR1.
    [Show full text]
  • Loss-Of-Function Mutation in the Prokineticin 2 Gene Causes
    Loss-of-function mutation in the prokineticin 2 gene SEE COMMENTARY causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism Nelly Pitteloud*†, Chengkang Zhang‡, Duarte Pignatelli§, Jia-Da Li‡, Taneli Raivio*, Lindsay W. Cole*, Lacey Plummer*, Elka E. Jacobson-Dickman*, Pamela L. Mellon¶, Qun-Yong Zhou‡, and William F. Crowley, Jr.* *Reproductive Endocrine Unit, Department of Medicine and Harvard Reproductive Endocrine Science Centers, Massachusetts General Hospital, Boston, MA 02114; ‡Department of Pharmacology, University of California, Irvine, CA 92697; §Department of Endocrinology, Laboratory of Cellular and Molecular Biology, Institute of Molecular Pathology and Immunology, University of Porto, San Joa˜o Hospital, 4200-465 Porto, Portugal; and ¶Departments of Reproductive Medicine and Neurosciences, University of California at San Diego, La Jolla, CA 92093 Communicated by Patricia K. Donahoe, Massachusetts General Hospital, Boston, MA, August 14, 2007 (received for review May 8, 2007) Gonadotropin-releasing hormone (GnRH) deficiency in the human associated with KS, although no functional data on the mutant presents either as normosmic idiopathic hypogonadotropic hypo- proteins were provided (17). Herein, we demonstrate that homozy- gonadism (nIHH) or with anosmia [Kallmann syndrome (KS)]. To gous loss-of-function mutations in the PROK2 gene cause IHH in date, several loci have been identified to cause these disorders, but mice and humans. only 30% of cases exhibit mutations in known genes. Recently, murine studies have demonstrated a critical role of the prokineticin Results pathway in olfactory bulb morphogenesis and GnRH secretion. Molecular Analysis of PROK2 Gene. A homozygous single base pair Therefore, we hypothesize that mutations in prokineticin 2 deletion in exon 2 of the PROK2 gene (c.[163delA]ϩ [163delA]) (PROK2) underlie some cases of KS in humans and that animals was identified in the proband, in his brother with KS, and in his deficient in Prok2 would be hypogonadotropic.
    [Show full text]
  • Kallmann Syndrome
    Kallmann syndrome Author: DoctorJean-Pierre Hardelin1 Creation date: July 1997 Updates: May 2002 December 2003 February 2005 Scientific editor: Professor Philippe Bouchard 1 Unité de Génétique des Déficits Sensoriels (INSERM U587), Institut Pasteur, 25 rue du Dr Roux, 75724 Paris cedex 15, France. [email protected] Abstract Keywords Disease name and synonyms Excluded diseases Diagnostic criteria / Definition Differential diagnosis Incidence Clinical description Management including treatment Etiology Diagnostic methods Genetic counseling Prenatal diagnosis Unresolved questions and comments References Abstract Kallmann syndrome combines hypogonadotropic hypogonadism due to GnRH deficiency, with anosmia or hyposmia. Magnetic resonance imaging (MRI) shows hypoplasia or aplasia of the olfactory bulbs. The incidence is estimated at 1 case in 10,000 males and 1 case in 50,000 females. The main clinical features consist of the association of micropenis and cryptorchidism in young boys, the absence of spontaneous puberty, a partial or total loss of the sense of smell (anosmia). Other possible signs include mirror movements of the upper limbs (synkinesis), unilateral or bilateral renal aplasia, cleft lip/palate, dental agenesis, arched feet, deafness. Diagnostic methods consist of hormones evaluation (GnRH stimulation test) as well as qualitative and quantitative olfactometric evaluation. Hormonal replacement is used to induce puberty, and later, fertility. Kallmann syndrome is due to an impaired embryonic development of the olfactory system and the GnRH-synthesizing neurons. Sporadic cases have been predominantly reported. Three modes of inheritance have been described in familial forms: X-linked recessive, autosomal dominant, or more rarely autosomal recessive. To date, only two of the genes responsible for this genetically heterogeneous disease have been identified: KAL-1, responsible for the X-linked form and FGFR1, involved in the autosomal dominant form (KAL-2).
    [Show full text]
  • Gene Expression Profiling of Corpus Luteum Reveals the Importance Of
    bioRxiv preprint doi: https://doi.org/10.1101/673558; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Gene expression profiling of corpus luteum reveals the 2 importance of immune system during early pregnancy in 3 domestic sheep. 4 Kisun Pokharel1, Jaana Peippo2 Melak Weldenegodguad1, Mervi Honkatukia2, Meng-Hua Li3*, Juha 5 Kantanen1* 6 1 Natural Resources Institute Finland (Luke), Jokioinen, Finland 7 2 Nordgen – The Nordic Genetic Resources Center, Ås, Norway 8 3 College of Animal Science and Technology, China Agriculture University, Beijing, China 9 * Correspondence: MHL, [email protected]; JK, [email protected] 10 Abstract: The majority of pregnancy loss in ruminants occurs during the preimplantation stage, which is thus 11 the most critical period determining reproductive success. While ovulation rate is the major determinant of 12 litter size in sheep, interactions among the conceptus, corpus luteum and endometrium are essential for 13 pregnancy success. Here, we performed a comparative transcriptome study by sequencing total mRNA from 14 corpus luteum (CL) collected during the preimplantation stage of pregnancy in Finnsheep, Texel and F1 15 crosses, and mapping the RNA-Seq reads to the latest Rambouillet reference genome. A total of 21,287 genes 16 were expressed in our dataset. Highly expressed autosomal genes in the CL were associated with biological 17 processes such as progesterone formation (STAR, CYP11A1, and HSD3B1) and embryo implantation (eg.
    [Show full text]
  • Gonadotropin-Releasing Hormone Agonist Treatment of Girls with Constitutional Short Stature and Normal Pubertal Development
    0021-972X/96/$03.00/0 Vol. 81, No. 9 Journal of Clmcal Endocrinology and Metabolism Printed in U.S.A. Copyright 0 1996 by The Endocrine Society Gonadotropin-Releasing Hormone Agonist Treatment of Girls with Constitutional Short Stature and Normal Pubertal Development JEAN-CLAUDE CAREL, FRlkDliRIQUE HAY, RliGIS COUTANT, DANIlkLE RODRIGUE, AND JEAN-LOUIS CHAUSSAIN Downloaded from https://academic.oup.com/jcem/article/81/9/3318/2651102 by guest on 23 September 2021 INSERM U-342 and Department of Pediatric Endocrinology, University of Paris V, Hbpital Saint Vincent de Paul, Paris, France ABSTRACT interruption of treatment, bone age was 14.9 2 1.3 yr (~13.5 yr in all GnRH agonists have been proposed to improve final height in patients), height was 149.1 k 4 cm, and final height prognosis was patients with constitutional short stature. We treated 31 girls, aged 150.6 2 3.6 cm. Final height prognosis was 1 2 2.3 cm greater than 11.9 i 1 yr (mean t- SD), with short stature, recent pubertal onset and pretreatment height prognosis (P < 0.02) and 1.2 k 2.2 cm below the predicted final height of 155 cm or less with depot triptorelin. During height predicted at the end of the treatment (P < 0.01). No major the 23 2 4 months of treatment, bone age progression was 0.6 ? 0.3 side-effect was observed. Height SD score decreased during treatment bone age yr/yr, and growth velocity declined from 7 k 2 to 4 2 0.8 with GnRH agonist from -2.3 ? 0.9 to -2.7 -C 0.7 SD score (P < cm/yr (P < 0.0001).
    [Show full text]
  • Dental-Craniofacial Manifestation and Treatment of Rare Diseases
    International Journal of Oral Science www.nature.com/ijos REVIEW ARTICLE OPEN Dental-craniofacial manifestation and treatment of rare diseases En Luo1, Hanghang Liu1, Qiucheng Zhao1, Bing Shi1 and Qianming Chen1 Rare diseases are usually genetic, chronic and incurable disorders with a relatively low incidence. Developments in the diagnosis and management of rare diseases have been relatively slow due to a lack of sufficient profit motivation and market to attract research by companies. However, due to the attention of government and society as well as economic development, rare diseases have been gradually become an increasing concern. As several dental-craniofacial manifestations are associated with rare diseases, we summarize them in this study to help dentists and oral maxillofacial surgeons provide an early diagnosis and subsequent management for patients with these rare diseases. International Journal of Oral Science (2019) 11:9 ; https://doi.org/10.1038/s41368-018-0041-y INTRODUCTION In this review, we aim to summarize the related manifestations Recently, the National Health and Health Committee of China first and treatment of dental-craniofacial disorders related to rare defined 121 rare diseases in the Chinese population. The list of diseases, thus helping to improve understanding and certainly these rare diseases was established according to prevalence, diagnostic capacity for dentists and oral maxillofacial surgeons. disease burden and social support, medical technology status, and the definition of rare diseases in relevant international institutions. Twenty million people in China were reported to suffer from these DENTAL-CRANIOFACIAL DISORDER-RELATED RARE DISEASES rare diseases. Tooth dysplasia A rare disease is any disease or condition that affects a small Congenital ectodermal dysplasia.
    [Show full text]
  • Case Report Kallmann's Syndrome: Clues to Clinical Diagnosis
    International Journal of Impotence Research (2000) 12, 121±123 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Case Report Kallmann's Syndrome: clues to clinical diagnosis H John1* and C Schmid2 Departments of 1Urology and 2Medicine (Division of Endocrinology), ZuÈrich University Hospital, Switzerland Hypogonadotropic patients may visit pediatricians, general practitioners, endocrinologists or urologists, presenting with microphallus, cryptochidism or pubertas tarda and delayed bone maturation. Congenital hypogonadotropic hypogonadism is characterized, apart from small testes, by the constellation of low serum levels of testosterone, LH and FSH. Kallman's syndrome is characterized by congenital hypogonadotropic hypogonadism with midline defects such as anosmia (a de®ciency of the sense of smell).1 The ®rst case report dates back to 1856,2 and genetic defects causing the syndrome have been recently described.3 The diagnosis can be clinically suspected and is established by con®rming hormonal studies. International Journal of Impotence Research (2000) 12, 121±123. Case Reports Case 2 Case 1 A 24-year-old patient consulted a general practi- tioner (the ®rst to address the problem of delayed puberty) for upper airway disease. He presented A 26-year old man fell on his right hand. The X-ray with an unbroken voice and sparse axillary and of the wrist (Figure 1) not only demonstrated the pubic body hair. He had a microphallus and fracture of the ®fth metacarpus but also an open testicular volumes of 2 ml, and a bone age of 17 epiphyseal line, thus revealing markedly delayed years. He did not smell garlic or curry.
    [Show full text]
  • Update on New GH-IGF Axis Genetic Defects
    review Update on new GH-IGF axis genetic defects Gabriela A. Vasques1,2 1 Unidade de Endocrinologia https://orcid.org/0000-0002-6455-8682 Genética, Laboratório de Endocrinologia Celular e Nathalia L. M. Andrade1,2 https://orcid.org/0000-0002-1628-7881 Molecular (LIM25), Hospital das Clínicas, Faculdade de Fernanda A. Correa2 Medicina, Universidade de São https://orcid.org/0000-0003-2107-9494 Paulo, São Paulo, SP, Brasil 2 Alexander A. L. Jorge1,2 Unidade de Endocrinologia do https://orcid.org/0000-0003-2567-7360 Desenvolvimento, Laboratório de Hormônios e Genética Molecular (LIM42), Hospital das Clínicas, Faculdade de ABSTRACT Medicina, Universidade de São The somatotropic axis is the main hormonal regulator of growth. Growth hormone (GH), also known Paulo, São Paulo, SP, Brasil as somatotropin, and insulin-like growth factor 1 (IGF-1) are the key components of the somatotropic axis. This axis has been studied for a long time and the knowledge of how some molecules could Correspondence to: promote or impair hormones production and action has been growing over the last decade. The Alexander A. L. Jorge Laboratório de Endocrinologia enhancement of large-scale sequencing techniques has expanded the spectrum of known genes and Celular e Molecular (LIM25), several other candidate genes that could affect the GH-IGF1-bone pathway. To date, defects in more Faculdade de Medicina, than forty genes were associated with an impairment of the somatotropic axis. These defects can Universidade de São Paulo Av. Dr. Arnaldo, 455, affect from the secretion of GH to the bioavailability and action of IGF-1. Affected patients present a 5º andar, sala 5.340 large heterogeneous group of conditions associated with growth retardation.
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Puberdade Precoce
    PUBERDADE PRECOCE Causas centrais JESUS BARREIRO-CONDE Bibliografia: Chen M, Eugster EA. Central Precocious Puberty: Update on Diagnosis and Treatment. Paediatr Drugs. 2015;17(4):273-81. Harrington J, Palmert M R. Definition, etiology, and evaluation of precocious puberty. En UpToDate. Hoppin A G, Martin K, Ed. 2018. Available at: http://www.UpToDate.com/ Bereket A. A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon Analog Treatment on Adult Height of Girls with Central Precocious Puberty. J Clin Res Pediatr Endocrinol. 2017 30;9(Suppl 2):33-48. MANUAL 2018 | CURSO TEÓRICO-PRÁTICO DE PUBERDADE 56 PUBERDADE PRECOCE | CAUSAS CENTRAIS | JESUS BARREIRO-CONDE HHS Public Access Author manuscript Author Manuscript Author Paediatr Drugs. Author manuscript; available in PMC 2018 March 27. Published in final edited form as: Paediatr Drugs. 2015 August ; 17(4): 273–281. doi:10.1007/s40272-015-0130-8. Central Precocious Puberty: Update on Diagnosis and Treatment Melinda Chen1 and Erica A. Eugster1 1Section of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, 705 Riley Hospital Drive, Room # 5960, Indianapolis, IN 46202, USA Author Manuscript Author Abstract Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ∼50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height.
    [Show full text]